NSE: SYNCOMF · PHARMACEUTICALS

Syncom Formulations (India) Limited Share Price & Company Info

₹21.19+4.44%

End-of-day price, · Educational content, not investment advice

52W low ₹10.2152W high ₹27.49
Market cap
₹1,809 Cras reported by NSE
52-week high
₹27.4930-SEP-2026
52-week low
₹10.2130-MAR-2026
P/E (NSE)
21.15sector P/E 21.14
Face value
₹1.00
Shares issued
94,00,00,000
Volume
3,99,48,940₹87.04 Cr traded
Delivery
20.77%of traded quantity
Price band
20%₹16.33 – ₹24.49 on 2026-11-02
Annual volatility
60.75%NSE, from daily returns
Series
EQrolling settlement
BSE group
Bscrip code 524470
ISIN
INE312C01025
Listed on NSE
18-Nov-2022

About Syncom Formulations (India) Limited

Syncom Formulations (India) Limited is listed on the National Stock Exchange of India under the symbol SYNCOMF in the EQ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 18-Nov-2022. Each share has a face value of ₹1.00.

In the end-of-day data for 16 November 2026 the stock closed at ₹21.19, up 4.44% on the day. NSE puts the company's market capitalisation at about ₹1,809 crore. Over the past 52 weeks it has traded between ₹10.21 and ₹27.49, so the last price is 107.5% above the low and 22.9% below the high.

3,99,48,940 shares changed hands that day, and 20.77% of them were taken as delivery rather than squared off intraday. A high delivery share means most of the day's buyers chose to hold the shares; a low one usually means the volume was mostly short-term trading.

EQ is the normal equity series: shares settle on the usual T+1 cycle and intraday trading is allowed.

NSE currently lists a regulatory note for this stock: “High low price var. was greater than 75% in prev. 3 mths. | High low price var. was greater than 100% in prev. 6 mths. | High low price var. was greater than 150% in prev. 12 mths”. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.

NSE puts the stock's annualised volatility at 60.75%. That is very high: moves of several percent in a single day are routine.

Because the share trades below ₹30, it also appears in our list of penny stocks under ₹30, which explains the extra risks that come with low-priced shares.

Syncom Formulations (India) Limited quarterly results

In the quarter ended June 2026 (un-audited), Syncom Formulations (India) Limited reported total income of ₹132 crore and a net profit of ₹24.59 crore, or ₹0.26 per share. That is a net margin of 18.6% on income.

A year earlier, in the June 2025 quarter, income was ₹123 crore with a net profit of ₹15.73 crore. Income has grown 8.1% year on year. Net profit has risen 56.3%.

Syncom Formulations (India) Limited was profitable in 5 of the 5 quarters shown below, every one of them. Figures are as filed with NSE, in ₹ crore.

Quarterly results filed with NSE (₹ crore, EPS in ₹)
Quarter endedTotal incomeProfit before taxNet profitEPSStatus
June 202613231.9124.590.26Un-Audited
March 202614832.8624.570.26Audited
December 202512025.0518.860.23Un-Audited
September 202512722.3616.840.18Un-Audited
June 202512320.2615.730.21Un-Audited

Syncom Formulations (India) Limited shareholding pattern

At the end of September 2026, promoters and the promoter group held 50.57% of Syncom Formulations (India) Limited, with the public holding 49.43%. The promoter stake has not changed across the 8 quarterly filings shown, from December 2024 to September 2026.

Shareholding by category, as filed with NSE each quarter
Quarter endedPromoter & Promoter Group (%)Public (%)
September 202650.5749.43
June 202650.5749.43
March 202650.5749.43
December 202550.5749.43
September 202550.5749.43
June 202550.5749.43
March 202550.5749.43
December 202450.5749.43

Syncom Formulations (India) Limited share price performance

Over the past year the Syncom Formulations (India) Limited share price has gained 15.85%, against a fall of 10.92% for the NIFTY 50, so it has outperformed that index by 26.77 percentage points.

Across the 6 periods in the table, the stock beat the NIFTY 50 in 5. Past returns describe what happened; they do not predict what comes next.

Price change by period, as of 2026-11-02 (NSE)
PeriodSYNCOMFNIFTY 50
1 month-23.05%+1.91%
3 months+48.35%-5.20%
6 months+40.47%-3.94%
1 year+15.85%-10.92%
2 years-2.72%-5.29%
3 years+128.40%+20.44%

Syncom Formulations (India) Limited vs industry peers

NSE compares Syncom Formulations (India) Limited with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.

Its P/E of 21.14 compares with a median of 27.25 for the other companies in the group.

NSE industry peer comparison, results for JUN 2026 quarter (₹ crore)
CompanyMarket capPrice (₹)P/EPromoter %Qtr incomeQtr net profit
HESTERBIO1,9642,309.0036.3953.7374.3414.71
INDOCO1,938210.00—58.8641382.32
PANACEABIO1,906311.10—72.481411.39
SYNCOMF1,81419.3021.1450.5713224.59
WINDLAS1,789867.0027.2163.3125317.65
VENUSREM1,6441,230.0013.6141.7618125.53
NGLFINE1,5672,536.9027.2872.4914416.45

Syncom Formulations (India) Limited announcements, board meetings and corporate actions

Latest announcements

The most recent filings Syncom Formulations (India) Limited has made with NSE, newest first:

  • 08-Oct-2026 · Certificate under SEBI (Depositories and Participants) Regulations, 2018: Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 (PDF)
  • 01-Oct-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
  • 01-Oct-2026 · Change in Management: Syncom Formulations (India) Limited has informed the Exchange about change in Management (PDF)
  • 01-Oct-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
  • 01-Oct-2026 · Shareholders meeting: Syncom Formulations (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results. (PDF)
  • 01-Oct-2026 · Shareholders meeting: Syncom Formulations (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026 (PDF)
  • 30-Sep-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
  • 26-Sep-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)

Board meetings

  • 11-Aug-2026 · Financial Results/Dividend/Other business matters: To consider and approve the financial results for the period ended Jun 30, 2026, dividend and other business matters
  • 22-May-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended March 31, 2026 and other business matters
  • 12-Feb-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended December 31, 2025 and other business matters
  • 12-Nov-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended September 30, 2025 and other business matters
  • 08-Aug-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters

Corporate actions

The corporate actions on record include 1 dividend. The ex-date is the first day the shares trade without the entitlement.

  • Dividend - Re 0.10 Per Share · ex-date 23-Sep-2026 · record date 23-Sep-2026
  • Annual General Meeting · ex-date 23-Sep-2024 · book closure 24-Sep-2024 to 30-Sep-2024
  • Annual General Meeting · ex-date 18-Sep-2023 · book closure 20-Sep-2023 to 26-Sep-2023

Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell Syncom Formulations (India) Limited.

Where to find Syncom Formulations (India) Limited's financials

Direct downloads from NSE:

For full financial statements, shareholding detail and every company announcement, go to the source:

Other Pharmaceuticals stocks on MCX Trends

Frequently asked questions

What is the Syncom Formulations (India) Limited share price?

Syncom Formulations (India) Limited (NSE: SYNCOMF) closed at ₹21.19 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.

Which sector does Syncom Formulations (India) Limited belong to?

NSE classifies Syncom Formulations (India) Limited under Pharmaceuticals, in the Healthcare sector.

What is the 52-week high and low of SYNCOMF?

The 52-week high is ₹27.49 (30-SEP-2026) and the 52-week low is ₹10.21 (30-MAR-2026), according to NSE.

Is Syncom Formulations (India) Limited a penny stock?

At ₹21.19 the share trades below ₹30, so it appears on our list of penny stocks under ₹30. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.

What is the promoter holding in Syncom Formulations (India) Limited?

Promoters and the promoter group held 50.57% of Syncom Formulations (India) Limited at the end of September 2026, according to the shareholding pattern filed with NSE.

What were Syncom Formulations (India) Limited's latest quarterly results?

For the quarter ended June 2026, Syncom Formulations (India) Limited reported total income of ₹132 crore and a net profit of ₹24.59 crore (EPS ₹0.26).

Where can I find Syncom Formulations (India) Limited's annual report and financial results?

Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for SYNCOMF) and on BSE. Screener also lays out several years of financial statements in one place. Links to all of these are above.

More on MCX Trends